Although the regulatory mechanisms of COX‐2 over‐expression in the pathogenesis of colorectal cancer have not been thoroughly investigated, the anticancer capability of both selective and non‐selective COX‐2 inhibitors has been demonstrated. Here, PTGS2 is linked to colorectal cancer.